TCGA-E2-A158-01A-11R-A12D-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 15
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- SPERMATOGENESIS+0.270
- MYC_TARGETS_V1+0.260
- E2F_TARGETS+0.240
- G2M_CHECKPOINT+0.230
- KRAS_SIGNALING_DN+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.150
- MITOTIC_SPINDLE+0.060
- DNA_REPAIR-0.030
- MYOGENESIS-0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.500
- ANGIOGENESIS-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- IL6_JAK_STAT3_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.440
- TNFA_SIGNALING_VIA_NFKB-0.410
- ALLOGRAFT_REJECTION-0.390
- APOPTOSIS-0.390
- COMPLEMENT-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1BWP5MCT | medulloblastoma | — | 0.945 |
| 2 | BS_D0RDN4K5 | Embryonal tumors | — | 0.941 |
| 3 | ERR2208946 | — | — | 0.933 |
| 4 | BS_9PB3XH5D | medulloblastoma | — | 0.931 |
| 5 | BS_W9AT0MR7 | medulloblastoma | — | 0.929 |
| 6 | BS_TE0GVDNG | medulloblastoma | — | 0.923 |
| 7 | TCGA-46-6026-01A-11R-1820-07 | — | cohortSQ1 | 0.923 |
| 8 | BS_GS1KR5PK | medulloblastoma | — | 0.921 |
| 9 | BS_3NWQXPQV | medulloblastoma | — | 0.920 |
| 10 | BS_QEYPFYHD | medulloblastoma | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |